This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Neuronal alpha-Synuclein Disease Integrated Staging System performance in PPMI, PASADENA, and SPARK baseline cohorts
- A staged screening protocol identifies people with biomarkers related to neuronal alpha-synuclein disease
- Responsivity of the striatal dopamine system to methylphenidate - a within-subject I-123-ss-CIT-SPECT study in children and adolescents with Attention-Deficit/Hyperactivity Disorder
- An Anthropomorphic Phantom Study of Brain Dopamine Transporter SPECT Images Obtained Using Different SPECT/CT Devices and Collimators
- Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study
- Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
- Assessing the Optimal Time Point for the Measurement of Extrastriatal Serotonin Transporter Binding with 123I-FP-CIT SPECT in Healthy, Male Subjects
- SNM Practice Guideline for Dopamine Transporter Imaging with 123I-Ioflupane SPECT 1.0
- Serotonin Transporters in Dopamine Transporter Imaging: A Head-to-Head Comparison of Dopamine Transporter SPECT Radioligands 123I-FP-CIT and 123I-PE2I
- The scientific and clinical basis for the treatment of Parkinson disease (2009)
- Reproducibility of a Standardized Quantitative Analysis Using Fixed Regions of Interest to Differentiate Movement Disorders on 123I-FP-CIT SPECT
- Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
- How useful is [123I]{beta}-CIT SPECT in clinical practice?
- Sensitivity and Specificity of 99mTc-TRODAT-1 SPECT Imaging in Differentiating Patients with Idiopathic Parkinson's Disease from Healthy Subjects
- Reproducibility of 99mTc-TRODAT-1 SPECT Measurement of Dopamine Transporters in Parkinson's Disease
- Dosimetry of the Dopamine Transporter Radioligand 18F-FPCIT in Human Subjects
- Quantification of Dopamine Transporter by 123I-PE2I SPECT and the Noninvasive Logan Graphical Method in Parkinson's Disease
- An algorithm (decision tree) for the management of Parkinson's disease (2001):: Treatment
- Brain SPECT in Neurology and Psychiatry
- Structural Changes of the Substantia Nigra in Parkinson's Disease as Revealed by MR Imaging
- Usefulness of a dopamine transporter PET ligand [18F]beta -CFT in assessing disability in Parkinson's disease
- Parkinson's disease: a novel MRI method for determining structural changes in the substantia nigra